Literature DB >> 31055844

Combination therapy of apremilast and secukinumab in patients with moderate-to-severe, recalcitrant plaque psoriasis.

L Sacchelli1, A Patrizi1, C Loi1, F Bardazzi1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31055844     DOI: 10.1111/ced.14000

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


× No keyword cloud information.
  4 in total

1.  Interleukin-17 Inhibitor Combination Therapies for the Treatment of Psoriasis: A Systematic Review.

Authors:  Amylee Martin; Akshitha Thatiparthi; Jeffrey Liu; Jashin J Wu
Journal:  J Clin Aesthet Dermatol       Date:  2022-06

2.  Combination Therapy with Apremilast and Biologics for Psoriasis: A Systematic Review.

Authors:  Mette Gyldenløve; Farzad Alinaghi; Claus Zachariae; Lone Skov; Alexander Egeberg
Journal:  Am J Clin Dermatol       Date:  2022-06-23       Impact factor: 6.233

Review 3.  [Treatment of psoriasis with secukinumab : Practical guidance].

Authors:  Andreas Körber; Matthias Augustin; Frank Behrens; Sascha Gerdes; Ralph von Kiedrowski; Knut Schäkel; Michael Sticherling; Dagmar Wilsmann-Theis; Johannes Wohlrab; Jan-Christoph Simon
Journal:  Hautarzt       Date:  2021-08-20       Impact factor: 0.751

4.  Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching.

Authors:  Giovanni Damiani; Giulia Odorici; Alessia Pacifico; Aldo Morrone; Rosalynn R Z Conic; Tima Davidson; Abdulla Watad; Paolo D M Pigatto; Delia Colombo; Piergiorgio Malagoli; Marco Fiore
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.